Three-month symptom profiles among symptomatic adults with positive and negative SARS-CoV-2 tests: a prospective cohort study from the INSPIRE group

Details

• Alternative Title:
  Clin Infect Dis
• Personal Author:
  Spatz, Erica S. ; Gottlieb, Michael ; Wisk, Lauren E. ; Anderson, Jill ; Chang, Anna Marie ; Gentile, Nicole L. ; Hill, Mandy J. ; Huebinger, Ryan M. ; Idris, Ahamed H. ; Kinsman, Jeremiah ; Koo, Katherine ; Li, Shu-Xia ; McDonald, Samuel ; Plumb, Ian D. ; Rodriguez, Robert ; Saydah, Sharon ; Slovis, Benjamin ; Stephens, Kari A ; Unger, Elizabeth R. ; Wang, Ralph C. ; Yu, Huihui ; Hota, Bala ; Elmore, Joann G. ; Weinstein, Robert A. ; Venkatesh, Arjun
• Description:
  BACKGROUND:
  
  Long-term symptoms following SARS-CoV-2 infection are a major concern, yet their prevalence is poorly understood.
  
  METHODS:
  
  We conducted a prospective cohort study comparing adults with SARS-CoV-2 infection (COVID+) with adults who tested negative (COVID−), enrolled within 28 days of an FDA-approved SARS-CoV2 test result for active symptoms. Sociodemographic characteristics, symptoms of SARS-CoV-2 infection (assessed with the CDC Person Under Investigation Symptom List), and symptoms of post-infectious syndromes (i.e., fatigue, sleep quality, muscle/joint pains, unrefreshing sleep, and dizziness/fainting, assessed with CDC Short Symptom Screener for myalgic encephalomyelitis/chronic fatigue syndrome) were assessed at baseline and 3 months via electronic surveys sent via text or email.
  
  RESULTS:
  
  Among the first 1,000 participants, 722 were COVID+ and 278 were COVID−. Mean age was 41.5 (SD 15.2); 66.3% were female, 13.4% were Black, and 15.3% were Hispanic. At baseline, SARS-CoV-2 symptoms were more common in the COVID+ group than the COVID− group. At 3-months, SARS-CoV-2 symptoms declined in both groups although were more prevalent in the COVID+ group: upper respiratory symptoms/head/eyes/ears/nose/throat (HEENT; 37.3% vs 20.9%), constitutional (28.8% vs 19.4%), musculoskeletal (19.5% vs 14.7%), pulmonary (17.6% vs 12.2%), cardiovascular (10.0% vs 7.2%), and gastrointestinal (8.7% vs 8.3%); only 50.2% and 73.3% reported no symptoms at all. Symptoms of post-infectious syndromes were similarly prevalent among the COVID+ and COVID− groups at 3 months.
  
  CONCLUSIONS:
  
  Approximately half of COVID+ participants, as compared with one-quarter of COVID− participants, had at least one SARS-CoV-2 symptom at 3 months, highlighting the need for future work to distinguish Long COVID.
  
  
• Subjects:
  Adult COVID-19 Female Humans Male Post-Acute COVID-19 Syndrome Prospective Studies SARS-CoV-2 Text Messaging
• Keywords:
  Coronavirus Long COVID Outcomes Registry
• Source:
  Clin Infect Dis. 76(9):1559-1566
• Pubmed ID:
  36573005
• Pubmed Central ID:
  PMC11361781
• Document Type:
  Journal Article
• Funding:
  75D30120C08008/IP/NCIRD CDC HHSUnited States/ ; 75D30120C08008/ImCDC/Intramural CDC HHSUnited States/
• Volume:
  76
• Issue:
  9
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha-512:a3fceb989e60949ab30fd03aaa6d0151ae7207280ab6694d3d6dfc35c75f6237897c1d52b80316bdc4b67a49c042802e130c418431445b1d5d56bbfcba4c9147
• Download URL:
  https://stacks.cdc.gov/view/cdc/160697/cdc_160697_DS1.pdf
• File Type:
  [PDF - 760.15 KB ]